Cereno Scientific reaffirms Q4 2028 topline, targets up to 15 sites by 2026

Cereno Scientific expects up to 15 trial sites activated by end-2026 in its Phase IIb EPIMODE PAH study and maintains anticipated topline results in Q4 2028, with recruitment targeted to complete during 2027.